Downsizing of the Foreign-Material Inspection Business for Pharmaceutical Containers
First written in FY2020-Q3. 4 of 18 entries say "Mitigated", first in FY2021-Q1. Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1Interim sales down, profit upAnnual report
「In the Other business, revenue for the six-month period was ¥6 million, down 27.0% year on year, and segment profit was ¥1 million, up 31.8%, mainly due to the foreign-material inspection business for pharmaceutical containers and related activities.」
The Other segment posted first-half revenue of ¥6 million, down 27.0% year on year, while segment profit was ¥1 million, up 31.8%. Following the recovery in full-year revenue in the previous fiscal year, revenue has declined again. - FY2025Full-year sales and profit recoveryAnnual report
「In the Other segment, including the foreign-matter inspection business for pharmaceutical containers, full-year sales were ¥16 million, up 120.5% year on year, and segment profit was ¥2 million, up 192.8%.」
The Other segment posted full-year revenue of ¥16 million and segment profit of ¥2 million, a significant recovery from the same period of the previous year. - FY2025-H1Interim sales and profit recoveryAnnual report
「③ Other segment In the Other segment, including the foreign-matter inspection business for pharmaceutical containers, sales for the interim accounting period were ¥8 million, up 155.2% year on year, and segment profit was ¥1 million, up 494.3%.」
Interim sales in the Other segment were ¥8 million and segment profit was ¥1 million, representing a substantial recovery from the same period of the previous year. However, the segment remains small relative to the company as a whole. - FY2024Full-year sales recoveryAnnual report
「In the Other segment, including the foreign-matter inspection business for pharmaceutical containers, full-year sales were ¥7 million, up 567.4% year on year, and segment profit was ¥0 million, up 14.5%.」
Full-year sales in the Other segment were ¥7 million, recovering from ¥1 million in the previous fiscal year. However, segment profit was ¥0 million and the business remains small in scale. - FY2024-Q2Second-quarter sales recoveryAnnual report
「In the Other segment, including the foreign-matter inspection business for pharmaceutical containers, sales for the cumulative second quarter were ¥3 million, up 622.0% year on year, while segment profit was ¥0 million, down 10.2%.」
Sales in the Other segment were ¥3 million, recovering from a low level with a 622.0% year-on-year increase. Segment profit was ¥0 million, down 10.2% year on year. - FY2024-Q1Low level continued in the first quarterAnnual report
「In the Other segment, including the foreign-matter inspection business for pharmaceutical containers, sales for the cumulative first quarter were ¥0 million, up 27.5% year on year, while segment loss was ¥0 million, compared with segment profit of ¥0 million in the same period of the previous year.」
Sales in the Other segment increased 27.5% year on year, but both sales and segment loss were ¥0 million, with the business remaining at a low level. - FY2023Full-year sales remained at ¥1 millionAnnual report
「In the Other segment, including the foreign-matter inspection business for pharmaceutical containers, full-year sales were ¥1 million, up 0.7% year on year, and segment profit was ¥0 million, up 42.1%.」
The Other segment had full-year sales of ¥1 million and segment profit of ¥0 million, with its business remaining at a low level. - FY2023-Q3Zero sales continued in the Other segmentAnnual report
「In the Other segment, including the foreign-matter inspection business for pharmaceutical containers, sales for the cumulative third quarter were ¥0 million, down 22.4% year on year, and segment profit was ¥0 million, up 8.5%.」
Both sales and segment profit in the Other segment were ¥0 million. Sales declined year on year, while segment profit increased, indicating that the segment remained at a low level rather than simply deteriorating. - FY2022WorsenedAnnual report
「In the Other segment, including the foreign-matter inspection business for pharmaceutical containers, full-year sales were ¥1 million, down 75.2% year on year, and segment profit was ¥0 million, down 82.8%.」
Sales in the Other segment were ¥1 million and segment profit was ¥0 million, representing a substantial year-on-year contraction. - FY2022-Q3Slight recovery in third-quarter salesAnnual report
「In the Other segment, including the foreign-matter inspection business for pharmaceutical containers, sales for the cumulative third quarter were ¥1 million, down 76.7% year on year, and segment profit was ¥0 million, down 83.9%.」
Sales in the Other segment were ¥1 million, up from ¥0 million in the cumulative previous quarter, but down 76.7% year on year. Segment profit was ¥0 million, down 83.9%. The contraction continued. - FY2022-Q2RestatedAnnual report
「In the Other segment, including the foreign-matter inspection business for pharmaceutical containers, sales for the cumulative second quarter were ¥0 million, down 89.6% year on year, and segment profit was ¥0 million, down 93.8%.」
Both sales and segment profit in the Other segment were ¥0 million, a substantial year-on-year decline. The contraction continued from the previous quarter. - FY2022-Q1WorsenedAnnual report
「In the Other segment, including the foreign-matter inspection business for pharmaceutical containers, sales for the cumulative first quarter were ¥0 million, down 95.2% year on year, and segment profit was ¥0 million, down 99.1%.」
Both sales and segment profit in the Other segment were ¥0 million, representing a substantial year-on-year decline. The segment contracted again in the first quarter after the recovery seen in the previous fiscal year. - FY2021MitigatedAnnual report
「In the Other segment, including the foreign-matter inspection business for pharmaceutical containers, full-year sales were ¥4 million, up 44.1% year on year, and segment profit was ¥2 million, up 73.4%.」
Both full-year sales and segment profit in the Other segment, which includes the foreign-matter inspection business for pharmaceutical containers, increased year on year, easing the contractionary trend. - FY2021-Q3MitigatedAnnual report
「In the Other segment, including the foreign-matter inspection business for pharmaceutical containers, sales for the cumulative third quarter were ¥4 million, up 56.2% year on year, and segment profit was ¥2 million, up 95.3%.」
Sales and segment profit in the Other segment, which includes the foreign-matter inspection business for pharmaceutical containers, increased year on year, and the contractionary trend seen through the previous fiscal year continued to ease. - FY2021-Q2MitigatedAnnual report
「In the Other segment, including the foreign-matter inspection business for pharmaceutical containers, sales for the cumulative second quarter were ¥2 million, up 175.3% year on year, and segment profit was ¥1 million, up 209.2%.」
Sales and segment profit in the Other segment, which includes the foreign-matter inspection business for pharmaceutical containers, increased year on year, easing the contractionary trend seen through the previous fiscal year. - FY2021-Q1MitigatedAnnual report
「In the Other segment, including the foreign-matter inspection business for pharmaceutical containers, sales for the cumulative first quarter were ¥1 million, up 76.3% year on year, and segment profit was ¥1 million, up 618.8%.」
Sales and segment profit in the Other segment, which includes the foreign-matter inspection business for pharmaceutical containers, increased year on year, easing the contractionary trend seen through the previous fiscal year. - FY2020WorsenedAnnual report
「In the Other segment, including the foreign-matter inspection business for pharmaceutical containers, sales were ¥3 million, down 62.5% year on year, and segment profit was ¥1 million, down 69.0%.」
Full-year sales in the Other segment were ¥3 million and segment profit was ¥1 million, down 62.5% and 69.0%, respectively, year on year. - FY2020-Q3First statedAnnual report
「In the Other segment, including the foreign-matter inspection business for pharmaceutical containers, sales for the cumulative third quarter were ¥2 million, down 52.3% year on year, and segment profit was ¥1 million, down 63.5%.」
Sales and segment profit in the foreign-matter inspection business for pharmaceutical containers, which is included in the Other segment, declined year on year during the cumulative third quarter.